Clinical Trials Browser

NCT07405476 2026-04-17

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Phase 2 Recruiting

38 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07494448 2026-03-27

JAZMINE

Phase 1/2 Not yet recruiting

24 enrolled

Breast

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07176312 2026-02-04

ZANGEA

Phase 2 Recruiting

80 enrolled

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT05035836 2025-12-22

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Phase 2 Recruiting

20 enrolled

Breast

Breast Neoplasms

NCT07296705 2025-12-22

HARBOR

Phase 2 Recruiting

25 enrolled

Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT07192068 2025-12-19

AcSé HER2

Phase 2 Recruiting

105 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Sarcoma, Colorectal Neoplasms

NCT07243938 2025-11-24

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

Phase 2 Not yet recruiting

70 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05615818 2025-04-23

SAFIR-ABC10

Phase 3 Recruiting

800 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05868226 2025-04-04

PRE-I-SPY-PI

Phase 1 Recruiting

124 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms